RHOA and skeletal dysplasia: Using the RhoA FRET biosensor to directly assess RhoA activation within MN-1 cells, we found that expression of WT and skeletal dysplasia mutant TRPV4, but not neuropathy mutant TRPV4, led to a significant decrease in RhoA FRET preferentially within the distal portion of neurite-like cellular processes (Fig. 6c, d and Supplementary Fig. 6b, c) as compared to cell bodies (Supplementary Fig. 6d–g).